1月20日 - ** 制药商BioXcel Therapeutics BTAI.O股价盘前下跌3.3%，至1.78美元
** 该公司称 (link) 它已请求美国 FDA 允许在家中使用 Igalmi 治疗与躁郁症和精神分裂症相关的躁动症
** BTAI表示，Igalmi是一种口腔溶解薄膜，于2022年获准在监督下使用，如果FDA同意，它将成为首个获批的家庭用药。
** 公司于 1 月 14 日通过补充申请提出申请
** 躁动是一种烦躁不安和强烈易怒的状态，可导致突然爆发；目前的治疗方案需要医疗监护 - BTAI
** 截至上次收盘，公司股价在过去一年中下跌了约 73%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.